

HTx: Next Generation Health Technology Assessment

Horizon 2020 project funded by the European Union (2019-2023)



Wim Goettsch^{1,2}

	Utrecht University (UU) Netherlands – Project Coordinator		University of Maastricht (UM) Netherlands		EURORDIS Rare Diseases Europe (EURORDIS) France
	University of Copenhagen (UoC) Denmark		University of Oulu (UoO) Finland		University of York (UoY) UK
	Medical University of Sofia (MUS) Bulgaria		University of Bern (UBERN) Switzerland		Universidad Politécnica de Madrid Spain
	European Organisation for Research and Treatment of Cancer (EORTC) Belgium		Dental and Pharmaceutical Benefits Agency (TLV) Sweden		National Health Care Institute (ZIN) Netherlands
	National Institute of Health and Care Excellence (NICE) UK		Syreon Research Institute (SRI) Hungary		Synapse research management (SYNAPSE) Spain



**HTx 2nd General Assembly
Bern, 6-7 February 2020**




© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.

1.Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands (w.g.goettsch@uu.nl)
2.National Health Care Institute (ZIN), Diemen, the Netherlands (wgoettsch@zinl.nl)

HTx objectives

- To **create a framework for next generation HTA** that supports **patient-centred, societally oriented, real-time decision-making** for **integrated healthcare** throughout **Europe**.
- To **facilitate the development of methodologies** to deliver more **customised information** on the **effectiveness** and **cost effectiveness** of **complex** and **personalised combinations** of health technologies.
- To provide methods to support **personalised treatment advice** that will be shared with **patients** and **their physicians**
- To **pilot implementation** of these methods in Europe with the HTA bodies (EUnetHTA) and their stakeholders







Case studies



- Proton therapy for head and neck cancer
- Monitoring and treatment pathways in diabetes (T1DM and T2DM)
- Pharmacological treatments for relapsing multiple sclerosis (MS)
- Different treatment modalities in patients with myelodysplastic syndrome (MDS)
- **Diagnostics and therapeutics for COVID**



Including development of framework to generalize results to other indications and settings












Results – stakeholder feedback

HTA stakeholders

Academics
Healthcare professionals
HTA bodies
Governments
Patients
Payers
Industry
.....



Roles in innovation



Beneficiaries
Practitioners
Developers





Developing a best-practice framework for the HTA of diagnostics and therapeutics for COVID-19

Identification

- **Identify HTA agencies' needs** in relation to assessment of COVID-19 technologies
- **Review currently available methods guidance** on the topic

Development

- **Develop a best-practice framework** for the assessment of COVID-19 technologies
- **Refine the framework** with stakeholders' input

Validation

- **Validate and test** the proposed framework in a sandbox environment. **Improve and adapt** based on outcome
- **Disseminate and encourage uptake and implementation**

